MX2015001428A - Composicion para el tratamiento del cancer asociado con la infeccion de hpv. - Google Patents

Composicion para el tratamiento del cancer asociado con la infeccion de hpv.

Info

Publication number
MX2015001428A
MX2015001428A MX2015001428A MX2015001428A MX2015001428A MX 2015001428 A MX2015001428 A MX 2015001428A MX 2015001428 A MX2015001428 A MX 2015001428A MX 2015001428 A MX2015001428 A MX 2015001428A MX 2015001428 A MX2015001428 A MX 2015001428A
Authority
MX
Mexico
Prior art keywords
composition
hpv
cancer associated
hpv infection
treating cancer
Prior art date
Application number
MX2015001428A
Other languages
English (en)
Inventor
Young Kee Shin
Young Deug Kim
Hu Soon Jung
Deuk Ae Kim
Original Assignee
Abion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abion Inc filed Critical Abion Inc
Publication of MX2015001428A publication Critical patent/MX2015001428A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Abstract

La presente invención refiere a una composición para prevenir o tratar enfermedades asociadas con el virus del papiloma humano (HPV), y más concretamente, cáncer asociado con HPV, y aún más concretamente, cáncer cervical. La secuencia de nucleótidos de la presente invención, la secuencia en la que se modifica su base, y su combinación específica puede ser útil en una composición para tratar efectivamente enfermedades asociadas con la infección de HPV inhibiendo grandemente la expresión del gen E6/E7 de HPV tipo 16 o 18.
MX2015001428A 2012-08-02 2013-08-01 Composicion para el tratamiento del cancer asociado con la infeccion de hpv. MX2015001428A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120084820A KR101520383B1 (ko) 2012-08-02 2012-08-02 Ｈｐｖ 감염과 관련된 암의 치료용 조성물
PCT/KR2013/006963 WO2014021667A1 (ko) 2012-08-02 2013-08-01 H p v 감염과 관련된 암의 치료용 조성물

Publications (1)

Publication Number Publication Date
MX2015001428A true MX2015001428A (es) 2016-01-20

Family

ID=50028269

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015001428A MX2015001428A (es) 2012-08-02 2013-08-01 Composicion para el tratamiento del cancer asociado con la infeccion de hpv.
MX2020002286A MX2020002286A (es) 2012-08-02 2015-01-30 Composicion para el tratamiento del cancer asociado con la infeccion del hpv.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020002286A MX2020002286A (es) 2012-08-02 2015-01-30 Composicion para el tratamiento del cancer asociado con la infeccion del hpv.

Country Status (13)

Country Link
US (3) US9719093B2 (es)
EP (6) EP3757213A1 (es)
JP (4) JP2015529654A (es)
KR (1) KR101520383B1 (es)
CN (1) CN104884096B (es)
AU (1) AU2013297196B2 (es)
BR (1) BR112015002177B1 (es)
CA (2) CA3075050C (es)
ES (1) ES2851904T3 (es)
MX (2) MX2015001428A (es)
RU (2) RU2636003C2 (es)
UA (1) UA117563C2 (es)
WO (1) WO2014021667A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105505929A (zh) * 2014-09-26 2016-04-20 中國香港貝億生物科技有限公司 针对hpv16e6基因的小干扰rna及其应用
KR20170139055A (ko) * 2015-04-16 2017-12-18 에이비온 주식회사 백금계 항암제에 의해 유도된 세포 내 증가된 p53 수준을 유지시키는 방법 및 이의 활용
KR20160133293A (ko) * 2015-05-12 2016-11-22 에이비온 주식회사 Hpv 바이러스의 발암 유전자 발현 저해물질을 유효성분으로 포함하는 암세포 감작용 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3257675B2 (ja) 1990-10-12 2002-02-18 マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． 修飾リボザイム
DE4216134A1 (de) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
WO1993023569A1 (en) * 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5716824A (en) 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
AU726047B2 (en) * 1995-11-15 2000-10-26 Gen-Probe Incorporated Nucleic acid probes complementary to human papillomavirus nucleic acid and related methods and kits
CA2253382A1 (en) 1996-01-16 1997-07-24 Ribozyme Pharmaceuticals, Inc. Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
DE19924668A1 (de) 1999-05-28 2000-11-30 Bayer Ag Substituierte alpha-Phenyl-beta-Ketosulfone
WO2003008573A2 (en) 2001-07-17 2003-01-30 Anne Josephine Milner Silencing of gene expression by sirna
JP4709545B2 (ja) 2002-07-26 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 修飾された低分子干渉ｒｎａ分子および使用方法
EP2000160A3 (en) * 2002-10-30 2009-03-11 Gambro Lundia AB Method and apparatuses for determining the efficiency of dialysis
EP2314691A3 (en) * 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
US20040198640A1 (en) * 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US7732166B2 (en) 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
RU2008141977A (ru) * 2006-03-24 2010-05-27 Новартис АГ (CH) КОМПОЗИЦИИ dsPHK И СПОСОБЫ ЛЕЧЕНИЯ HPV-ИНФЕКЦИИ
CN101410518A (zh) * 2006-03-24 2009-04-15 诺瓦提斯公司 治疗HPV感染的dsRNA组合物和方法
DE102006035618A1 (de) * 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
BRPI0716744A2 (pt) 2006-09-14 2016-10-04 Human Genome Sciences Inc proteínas de fusão de albumina
KR100962301B1 (ko) 2006-11-03 2010-06-11 재단법인서울대학교산학협력재단 자궁경부암을 위한 치료용 조성물
WO2008139938A1 (ja) * 2007-05-02 2008-11-20 National University Corporation Tokyo Medical And Dental University ヒトパピローマウイルス１６型遺伝子を標的とする二本鎖核酸分子及びそれを含む医薬
EP2176412B1 (en) * 2007-06-15 2017-09-13 Beth Israel Deaconess Medical Center Bacterial mediated tnf-alpha gene silencing
US20110130440A1 (en) * 2008-03-26 2011-06-02 Alnylam Pharmaceuticals, Inc. Non-natural ribonucleotides, and methods of use thereof
AU2009313930A1 (en) * 2008-11-14 2011-06-23 Marina Biotech, Inc. E. coli mediated gene silencing of beta-catenin
WO2010129941A1 (en) 2009-05-08 2010-11-11 Becton, Dickinson And Company Correlation of hpv e6 and e7 expression with progression of cervical disease
CN102740729B (zh) 2009-12-23 2014-12-10 高露洁-棕榄公司 口腔护理器具
KR101197627B1 (ko) * 2010-01-18 2012-11-07 (주)레퍼런스바이오랩 Ｈｐｖ 감염과 관련된 암의 치료용 조성물
WO2012016139A2 (en) * 2010-07-29 2012-02-02 Sirnaomics, Inc. Sirna compositions and methods for treatment of hpv and other infections

Also Published As

Publication number Publication date
BR112015002177B1 (pt) 2022-09-27
WO2014021667A1 (ko) 2014-02-06
CA2880777A1 (en) 2014-02-06
US10221418B2 (en) 2019-03-05
KR20140018560A (ko) 2014-02-13
CN104884096A (zh) 2015-09-02
US20170198291A1 (en) 2017-07-13
CA3075050C (en) 2022-05-17
US20180044679A1 (en) 2018-02-15
UA117563C2 (uk) 2018-08-27
RU2015106855A (ru) 2016-09-27
CN104884096B (zh) 2022-05-24
JP6727381B2 (ja) 2020-07-22
CA2880777C (en) 2020-06-30
EP3178498B1 (en) 2020-11-18
AU2013297196A1 (en) 2015-03-19
MX2020002286A (es) 2020-07-13
JP2019194234A (ja) 2019-11-07
JP2015529654A (ja) 2015-10-08
US9719093B2 (en) 2017-08-01
JP2018109058A (ja) 2018-07-12
EP3178498A2 (en) 2017-06-14
BR112015002177A2 (pt) 2017-11-07
RU2664466C1 (ru) 2018-08-17
EP3699278A1 (en) 2020-08-26
ES2851904T3 (es) 2021-09-09
EP2881123A1 (en) 2015-06-10
EP3722425A1 (en) 2020-10-14
AU2013297196B2 (en) 2017-01-05
CA3075050A1 (en) 2014-02-06
US20150299711A1 (en) 2015-10-22
KR101520383B1 (ko) 2015-05-15
EP2881123A4 (en) 2016-07-06
EP3699279A1 (en) 2020-08-26
EP3757213A1 (en) 2020-12-30
EP3178498A3 (en) 2017-09-27
RU2636003C2 (ru) 2017-11-17
JP2016190845A (ja) 2016-11-10
JP6347433B2 (ja) 2018-06-27

Similar Documents

Publication Publication Date Title
IN2015DN01156A (es)
PH12015501953A1 (en) Substituted nucleotide analogs
PH12015501423A1 (en) Substituted nucleosides, nucleotides and analogs thereof
TN2013000485A1 (en) 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
NZ630800A (en) Methods of preparing substituted nucleotide analogs
PH12014502496B1 (en) Bicyclically substituted uracils and the use thereof
NZ631537A (en) Compositions and methods for modulating apolipoprotein c-iii expression
NZ705360A (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
NZ630596A (en) Methods for treatment of alport syndrome
MY171831A (en) Novel fused pyrimidine compound or salt thereof
MX2019007057A (es) Composiciones de adenovirus.
EA201491676A1 (ru) Партии рекомбинантного аденовируса с измененными концевыми областями
MX2013012233A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas.
PH12015501076A1 (en) N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group
IN2014MN01493A (es)
MX357656B (es) Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
PH12014502551A1 (en) Oligonucleotide chelate complex-polypeptide compositions and methods
MX2020002286A (es) Composicion para el tratamiento del cancer asociado con la infeccion del hpv.
BR112015022308A8 (pt) oligonucleotídeos antissenso para o tratamento de células-tronco cancerosas
EP2593548A4 (en) ANTIGEN E7 COMPOSITIONS OF HUMAN PAPILLOMAVIRUS AND USES THEREOF
EA019080B9 (ru) α-КРИСТАЛЛИЧЕСКАЯ ФОРМА КАРБАБЕНЗПИРИДА
IN2014DN10683A (es)
UA82485U (ru) Печь для термической и химико-термической обработки деталей
NZ622284A (en) Novel plant defensins and use in the treatment of proliferative diseases

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ENHANCEDBIO INC.

FG Grant or registration